Guillain-Barre Syndrome (GBS)

01Pathophysiology

Guillain-Barré Syndrome (GBS) is the most common cause of acute flaccid paralysis in previously healthy individuals. The disease is driven by molecular mimicry: surface antigens on an infecting organism (most classically Campylobacter jejuni) share structural similarity with ganglioside components on peripheral nerve myelin or axonal membranes. The immune system, having mounted a response against the pathogen, cross-reacts with peripheral nerve tissue.

In the most common subtype, acute inflammatory demyelinating polyneuropathy (AIDP), the autoimmune attack targets the myelin sheath of peripheral nerves. Macrophages and complement-mediated injury strip away myelin, leading to saltatory conduction failure. This explains why nerve conduction studies show prolonged distal latencies and conduction block: the nerve impulse cannot jump efficiently between nodes of Ranvier. When enough myelin is destroyed, the nerve effectively stops conducting signals, producing flaccid paralysis and loss of deep tendon reflexes.

The reason weakness ascends from distal to proximal is anatomical: the longest peripheral nerves are affected first because they have more surface area vulnerable to immune attack, and the blood-nerve barrier is weakest at nerve roots and terminal segments. The pattern therefore begins in the feet and legs, climbs to the thighs and trunk, and may eventually involve the diaphragm and intercostal muscles. This is why respiratory failure is the most feared complication and the leading cause of death if not anticipated.

Cranial nerves, particularly facial nerve (CN VII), can also be involved because they are peripheral nerves. Bilateral facial weakness is a classic finding that distinguishes GBS from central nervous system pathology. Autonomic nerve fibers may also be affected, producing dysautonomia (labile blood pressure, cardiac arrhythmias, urinary retention), which is an underrecognized cause of mortality in these patients.

Importantly, GBS is a lower motor neuron disease. This is why the exam findings include flaccid (not spastic) paralysis, absent (not hyperactive) reflexes, and no upper motor neuron signs such as Babinski sign or clonus.

02Classification and Clinical Manifestation

The most important distinction for exam purposes is between AIDP (demyelinating, the prototype) and Miller Fisher Syndrome (the triad of ophthalmoplegia, ataxia, and areflexia with anti-GQ1b antibodies). A vignette describing eye movement abnormalities with ataxia and absent reflexes after a recent infection should point directly to Miller Fisher.

03Diagnostic Workup

The clinical diagnosis of GBS is primarily made at the bedside. When a patient presents with rapidly progressive, symmetric ascending weakness with areflexia following a recent infection, GBS should be at the top of the differential.

Lumbar puncture is the best initial test ordered to support the clinical suspicion. The hallmark finding is albuminocytologic dissociation, meaning the CSF protein is elevated while the white blood cell count remains normal. This pattern occurs because inflammation at the nerve roots disrupts the blood-nerve barrier, allowing protein to leak into the CSF, but there is no infectious or inflammatory cellular infiltrate in the subarachnoid space. A critical exam point: if the CSF shows elevated WBC (pleocytosis) along with elevated protein, you must consider alternative diagnoses such as HIV-associated polyradiculopathy, Lyme disease, CMV radiculitis, or leptomeningeal carcinomatosis. Another important caveat is that the CSF may be entirely normal within the first 48 to 72 hours of symptom onset, so a normal LP very early in the course does not exclude GBS.

Nerve conduction studies and electromyography (NCS/EMG) are the most accurate confirmatory test. In AIDP, the classic findings are prolonged distal motor latencies, slowed conduction velocities, conduction block, and prolonged or absent F-waves. These findings reflect the underlying segmental demyelination. In axonal variants (AMAN, AMSAN), conduction velocities may be preserved but amplitudes are reduced, indicating axonal loss rather than myelin damage. Like the LP, NCS/EMG may be normal very early in the disease course, and repeat testing at 1 to 2 weeks may be needed.

Respiratory monitoring deserves its own emphasis because it is the most testable management decision. Serial measurements of FVC and NIF (negative inspiratory force) are not diagnostic for GBS per se, but they determine the single most important clinical action: when to intubate. The "20/30/40 rule" is a useful framework:

• FVC < 20 mL/kg

• NIF weaker than -30 cmH₂O (that is, the patient cannot generate adequate negative pressure)

• More than 40% decline in FVC from baseline

Any of these thresholds warrants elective intubation. Do not wait for arterial blood gas abnormalities or clinical signs of respiratory distress, as these are late findings in neuromuscular respiratory failure. Pulse oximetry is also unreliable in this setting because oxygen saturation may remain normal until the patient is on the verge of respiratory arrest.

04Management and Treatment

The acute management of GBS centers on two parallel priorities: immunomodulatory therapy and airway protection.

IVIG at a dose of 0.4 g/kg/day for 5 consecutive days is the most commonly chosen first-line therapy. It works by neutralizing pathogenic antibodies, modulating complement activation, and downregulating the autoimmune response. It is generally preferred over plasmapheresis because it is easier to administer, does not require central venous access, and has fewer hemodynamic complications. Side effects include headache, aseptic meningitis, renal toxicity (particularly with sucrose-containing formulations), and thromboembolic events.

Plasmapheresis (therapeutic plasma exchange, TPE) is equally effective and involves physically removing circulating autoantibodies from the patient's blood. It is typically delivered as 5 exchanges over 7 to 14 days. It is preferred when IVIG is contraindicated, such as in patients with IgA deficiency (who may develop anaphylaxis to IVIG) or severe renal insufficiency.

A critically testable point: do not combine IVIG and plasmapheresis. Clinical trials have shown that combining them provides no additional benefit over either alone, and plasmapheresis would simply wash out the administered immunoglobulin.

Corticosteroids have no role in the treatment of GBS. Despite their efficacy in many other autoimmune conditions, multiple randomized controlled trials have demonstrated that corticosteroids do not improve outcomes in GBS and may even delay recovery. This is one of the most frequently tested "traps" on licensing exams.

The second priority is respiratory management. The most important clinical decision in GBS is determining when to intubate. Because GBS causes neuromuscular respiratory failure (the lungs themselves are normal, but the muscles of breathing are weak), standard indicators like oxygen saturation and arterial blood gas are insensitive until very late. Instead, bedside pulmonary function testing with FVC and NIF should be performed every 4 to 6 hours. Elective intubation is safer and preferred over emergent intubation in a patient who is acutely decompensating.

Additional supportive measures include:

• DVT prophylaxis with subcutaneous heparin, as immobilized patients are at high risk for venous thromboembolism

• Neuropathic pain control with gabapentin or pregabalin, since pain is reported in up to 70% of GBS patients and is frequently undertreated

• Autonomic monitoring with continuous telemetry, because dysautonomia (tachycardia, bradycardia, blood pressure swings) is a significant contributor to mortality

• Early rehabilitation with physical and occupational therapy once the patient is clinically stable, as this is the primary determinant of long-term functional recovery

Most patients with GBS recover, though recovery may take weeks to months. Approximately 80% of patients regain the ability to walk independently within 6 months, though residual fatigue and minor weakness are common. About 5 to 10% of patients experience incomplete recovery with significant disability, and 3 to 5% die, most often from respiratory failure, pulmonary embolism, or cardiac arrest from dysautonomia.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common way students lose points on GBS questions is by selecting corticosteroids as treatment. Because GBS is autoimmune and because corticosteroids work in nearly every other autoimmune neurological condition (multiple sclerosis, myasthenia gravis, CIDP), it is natural to assume they would work here. They do not. This is a deliberately placed distractor, and the correct answers are always IVIG or plasmapheresis.

The second major trap involves respiratory monitoring. A vignette may describe a patient with GBS who "appears comfortable" and has normal oxygen saturation, then ask for the next best step. Students who select "continue observation" or "obtain an ABG" will miss the point. The correct answer is serial FVC measurement, because neuromuscular respiratory failure is a ventilatory problem (inadequate air movement), not an oxygenation problem. By the time the oxygen saturation drops or the ABG shows CO₂ retention, the patient is in extremis.

A third testing angle involves early normal CSF. A question may present a patient with classic GBS symptoms but a normal lumbar puncture. Students must recognize that the CSF protein elevation may take several days to develop, and a normal LP within the first 48 to 72 hours does not exclude the diagnosis. The next step in this scenario is to proceed with nerve conduction studies or to repeat the LP later.

For Miller Fisher Syndrome, the tested competency is recognizing the triad (ophthalmoplegia, ataxia, areflexia) and linking it to anti-GQ1b antibodies. This variant can appear as a standalone question or as a distractor designed to mimic brainstem stroke or Wernicke encephalopathy. The absence of altered mental status and the presence of areflexia should steer you toward Miller Fisher.

Finally, remember the distinction between GBS and CIDP. Both are demyelinating polyradiculoneuropathies with similar CSF and NCS findings. The discriminator is time course: GBS reaches its nadir within 4 weeks and then plateaus or improves. If symptoms continue to progress beyond 8 weeks, the diagnosis shifts to CIDP, which does respond to corticosteroids. This distinction is a favorite testing point for differentiating acute from chronic autoimmune neuropathy.

The core competency being tested across all GBS questions is the ability to recognize a post-infectious ascending paralysis, order the correct diagnostic tests in the correct sequence, initiate appropriate immunotherapy while avoiding corticosteroids, and anticipate respiratory failure before it becomes clinically apparent.